|
PTGR2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63158375698913E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.475550E-02 |
| Normal-vs-Stage3 |
2.37910025013832E-10 |
| Normal-vs-Stage4 |
9.11271058612328E-13 |
| Stage1-vs-Stage2 |
9.343800E-03 |
| Stage1-vs-Stage3 |
7.999400E-01 |
| Stage1-vs-Stage4 |
8.486400E-02 |
| Stage2-vs-Stage3 |
1.169540E-02 |
| Stage2-vs-Stage4 |
1.240130E-03 |
| Stage3-vs-Stage4 |
2.767000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.99840144432528E-15 |
| Normal-vs-AfricanAmerican |
2.025700E-04 |
| Normal-vs-Asian |
3.45068418283745E-12 |
| Caucasian-vs-AfricanAmerican |
3.493000E-01 |
| Caucasian-vs-Asian |
1.688770E-01 |
| AfricanAmerican-vs-Asian |
1.622240E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.1227464230833E-13 |
| Normal-vs-Female |
2.01039185299123E-12 |
| Male-vs-Female |
5.741800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.20914430982111E-12 |
| Normal-vs-Age(41-60Yrs) |
4.70880001657292E-10 |
| Normal-vs-Age(61-80Yrs) |
6.75430000818267E-09 |
| Normal-vs-Age(81-100Yrs) |
6.165400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.198810E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.575400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.948800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.684200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.579400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.416600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.902630E-01 |
| Classical-VS-Follicular |
1.98076999999852E-05 |
| Classical-VS-Other |
1.731770E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.59019999999011E-05 |
| Tall-VS-Other |
3.543800E-02 |
| Tall-VS-Normal |
2.44250175640559E-11 |
| Follicular-VS-Other |
7.280200E-01 |
| Follicular-VS-Normal |
1.978030E-03 |
| Other-VS-Normal |
5.754300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.66689995140246E-10 |
| Normal-vs-N1 |
2.08966177694947E-12 |
| N0-vs-N1 |
6.518900E-03 |
|
|
